CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria

Diagnostic Microbiology and Infectious Disease

Volumn 66, Issue 4, 2010, Pages 393-401

  Putnam, Shannon D ^a,b   Castanheira, Mariana ^a   Moet, Gary J ^a   Farrell, David J ^a   Jones, Ronald N ^a,c  

^a JMI LABORATORIES   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antimicrobial susceptibility; CEM 101; Fluoroketolide

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; CEFDINIR; CEFTRIAXONE; CEM 101; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; IMIPENEM; KETOLIDE; LEVOFLOXACIN; LINEZOLID; METRONIDAZOLE; PENICILLIN G; TELITHROMYCIN; TETRACYCLINE; UNCLASSIFIED DRUG;

AEROBIC BACTERIUM; AEROCOCCUS; AEROCOCCUS VIRIDANS; ALPHA HEMOLYTIC STREPTOCOCCUS; ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACILLUS; BACTEROIDES FRAGILIS; CAMPYLOBACTER JEJUNI; CLOSTRIDIUM; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; CORYNEBACTERIUM; DERMABACTER HOMINIS; DRUG POTENCY; DRUG STRUCTURE; GEMELLA MORBILLORUM; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HELICOBACTER PYLORI; LACTOCOCCUS LACTIS; LISTERIA MONOCYTOGENES; MICROCOCCUS; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA GONORRHOEAE; NONHUMAN; PEPTOSTREPTOCOCCUS; PORPHYROMONAS; PREVOTELLA; PRIORITY JOURNAL; ROTHIA; ROTHIA MUCILAGINOSA; SALMONELLA; SHIGELLA; WEISSELLA CONFUSA;

ANTI-BACTERIAL AGENTS; BACTERIA, AEROBIC; BACTERIA, ANAEROBIC; BACTERIAL INFECTIONS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MACROLIDES; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; TRIAZOLES;

EID: 77649339337     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2009.10.013     Document Type: Article

References (37)

1. Azoulay-Dupuis E., Bedos J.P., Mohler J., Schmitt-Hoffmann A., Schleimer M., and Shapiro S. Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia. Antimicrob. Agents Chemother. 48 (2004) 1105-1111
2. Biedenbach D.J., Deshpande L.M., Fritsche T.T., Sader H.S., and Jones R.N. Antimicrobial characterization of CEM-101: activity against enterococci, uncommon Gram-positive pathogens, N. gonorrhoeae and anaerobes. 48th ICAAC, October 25-28, 2008. pp. Abstr. F1-9376. Washington, DC, USA (2008)
3. Brinker A.D., Wassel R.T., Lyndly J., Serrano J., Avigan M., Lee W.M., and Seeff L.B. Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases. Hepatology 49 (2009) 250-257
4. Canu A., Malbruny B., Coquemont M., Davies T.A., Appelbaum P.C., and Leclercq R. Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 46 (2002) 125-131
5. Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines. MMWR: CDC (2006). http://www.cdc.gov/std/treatment/2006/toc.htm
6. Cetin E.S., Gunes H., Kaya S., Aridogan B.C., and Demirci M. Macrolide-lincosamide-streptogramin B resistance phenotypes in clinical staphylococcal isolates. Int. J. Antimicrob. Agents 31 (2008) 364-368
7. Chisholm S.A., Neal T.J., Alawattegama A.B., Birley H.D., Howe R.A., and Ison C.A. Emergence of high-level azithromycin resistance in Neisseria gonorrhoeae in England and Wales. J. Antimicrob. Chemother. 64 (2009) 353-358
8. Clay K.D., Hanson J.S., Pope S.D., Rissmiller R.W., Purdum III P.P., and Banks P.M. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann. Intern. Med. 144 (2006) 415-420
9. Clinical and Laboratory Standards Institute (CLSI). Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria, M45-A (2006), CLSI, Wayne, PA
10. Clinical and Laboratory Standards Institute (CLSI). Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard-seventh edition, M11-A7 (2008), CLSI, Wayne, PA
11. Clinical and Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-eighth edition, M07-A8 (2009), CLSI, Wayne, PA
12. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: 19th informational supplement (M100-S19) (2009), CLSI, Wayne, PA
13. Gherardi G., De Florio L., Lorino G., Fico L., and Dicuonzo G. Macrolide resistance genotypes and phenotypes among erythromycin-resistant clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci, Italy. FEMS. Immunol. Med. Microbiol. 55 (2009) 62-67
14. Jones R.N., Biedenbach D.J., Rhomberg P.R., Fritsche T.R., and Sader H.S. Antimicrobial characterization of CEM-101 activity against 331 respiratory tract pathogens including multidrug-resistant pneumococcal serogroup 19A (MDR-19A) isolates. 48th ICAAC, October 25-28, 2008. pp. Abstr. F1-3975. Washington, DC, USA (2008)
15. Jones R.N., Sader H.S., Fritsche T.R., Biedenbach D.J., and Castanheira M. Antimicrobial characterization of CEM-101: potential application against species causing enteritis/gastroenteritis. 48th ICAAC, October 25-28, 2008. pp. Abstr. F1-3977. Washington, DC, USA (2008)
16. Kouvela E.C., Kalpaxis D.L., Wilson D.N., and Dinos G.P. Distinct mode of interaction of a novel ketolide antibiotic that displays enhanced antimicrobial activity. Antimicrob. Agents Chemother. 53 (2009) 1411-1419
17. Kuipers E.J., Nelis G.F., Klinkenberg-Knol E.C., Snel P., Goldfain D., Kolkman J.J., Festen H.P., Dent J., Zeitoun P., Havu N., Lamm M., and Walan A. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut 53 (2004) 12-20
18. Lemaire S., Van Bambeke F., and Tulkens P.M. Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. Antimicrob. Agents Chemother. 53 (2009) 3734-3743
19. Lim J.A., Kwon A.R., Kim S.K., Chong Y., Lee K., and Choi E.C. Prevalence of resistance to macrolide, lincosamide and streptogramin antibiotics in Gram-positive cocci isolated in a Korean hospital. J. Antimicrob. Chemother. 49 (2002) 489-495
20. Limbago B.M., Long C.M., Thompson A.D., Killgore G.E., Hannett G.E., Havill N.L., Mickelson S., Lathrop S., Jones T.F., Park M.M., Harriman K.H., Gould L.H., McDonald L.C., and Angulo F.J. Clostridium difficile strains from community-associated infections. J. Clin. Microbiol. 47 (2009) 3004-3007
21. Llano-Sotelo B., Klepacki D., and Mankinb A.S. Binding and action of CEM-101, a new macrolide/ketolide in development for treating infections with macrolide-resistant and macrolide-susceptible bacteria. 48th ICAAC, October 25-28, 2008. pp. Abstr. F-3983. Washington DC, USA (2008)
22. McGhee P., Clark C., Kosowska-Shick K., Nagai K., Dewasse B., Beachel L., and Appelbaum P.C. In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. Antimicrob. Agents Chemother. (2009) (in press)
23. Onur O., Guneysel O., Denizbasi A., and Celikel C. Acute hepatitis attack after exposure to telithromycin. Clin. Ther. 29 (2007) 1725-1729
24. Palmer H.M., Young H., Winter A., and Dave J. Emergence and spread of azithromycin-resistant Neisseria gonorrhoeae in Scotland. J. Antimicrob. Chemother. 62 (2008) 490-494
25. Roblin P.M., Kohloff S.A., and Hammerschlag M.R. In vitro activity of CEM101, a new ketolide antibiotic against Chlamydia trachomatis and Chlamydia pneumoniae. 48th ICAAC, October 25-28, 2008. pp. Abstr. F1-3978. Washington, DC, USA (2008)
26. Sader H.S., Biedenbach D.J., Rhomberg P.R., and Jones R.N. Antimicrobial characterization of CEM-101: PAE, bactericidal activity and combinations. 48th ICAAC, October 25-28, 2008. pp. Abstr. F1-3981. Washington, DC, USA (2008)
27. Sanders J.W., Frenck R.W., Putnam S.D., Riddle M.S., Johnston J.R., Ulukan S., Rockabrand D.M., Monteville M.R., and Tribble D.R. Azithromycin and loperamide are comparable to levofloxacin and loperamide for the treatment of traveler's diarrhea in United States military personnel in Turkey. Clin. Infect. Dis. 45 (2007) 294-301
28. Serichantalergs O., Jensen L.B., Pitarangsi C., Mason C.J., and Dalsgaard A. A possible mechanism of macrolide resistance among multiple resistant Campylobacter jejuni and Campylobacter coli isolated from Thai children during 1991-2000. Southeast Asian J. Trop. Med. Public Health 38 (2007) 501-506
29. Starnino S., and Stefanelli P. Azithromycin-resistant Neisseria gonorrhoeae strains recently isolated in Italy. J. Antimicrob. Chemother. 63 (2009) 1200-1204
30. Suerbaum S., and Michetti P. Helicobacter pylori infection. N. Engl. J. Med. 347 (2002) 1175-1186
31. Tapsall J.W. Antibiotic resistance in Neisseria gonorrhoeae. Clin. Infect. Dis. 41 Suppl 4 (2005) 263-268
32. Tapsall J.W., Shultz T.R., Limnios E.A., Donovan B., Lum G., and Mulhall B.P. Failure of azithromycin therapy in gonorrhea and discorrelation with laboratory test parameters. Sex. Transm. Dis. 25 (1998) 505-508
33. Tribble D.R., Sanders J.W., Pang L.W., Mason C., Pitarangsi C., Baqar S., Armstrong A., Hshieh P., Fox A., Maley E.A., Lebron C., Faix D.J., Lawler J.V., Nayak G., Lewis M., Bodhidatta L., and Scott D.A. Traveler's diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. Clin. Infect. Dis. 44 (2007) 338-346
34. Vale F.F., Megraud F., and Vitor J.M. Geographic distribution of methyltransferases of Helicobacter pylori: evidence of human host population isolation and migration. BMC Microbiol. 9 (2009) 193
35. Waites K.B., Crabb D.M., and Duffy L.B. Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101. Antimicrob. Agents. Chemother. 53 (2009) 2139-2141
36. Workowski K.A., Berman S.M., and Douglas Jr. J.M. Emerging antimicrobial resistance in Neisseria gonorrhoeae: urgent need to strengthen prevention strategies. Ann. Intern. Med. 148 (2008) 606-613
37. Zarantonelli L., Borthagaray G., Lee E.H., Veal W., and Shafer W.M. Decreased susceptibility to azithromycin and erythromycin mediated by a novel mtr(R) promoter mutation in Neisseria gonorrhoeae. J. Antimicrob. Chemother. 47 (2001) 651-654